ClinicalTrials.Veeva

Menu
K

Kaiser Permanente | Division of Research

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

VX-121
VX-445
CTP-543
Icosapent Ethyl
Olaparib
Ritlecitinib
BMS-986036
pegcrisantaspase
Selpercatinib
Lenacapavir

Parent organization

This site is a part of Kaiser Permanente

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 25 total trials

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental viti...

Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in pa...

Active, not recruiting
Cystic Fibrosis
Drug: VX-121/TEZ/D-IVA

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.

Active, not recruiting
FIGO Stage III-IV
Newly Diagnosed
Drug: Olaparib 300mg tablets
Recently updated

The goal of this clinical study is to test how well the study drug, lenacapavir (LEN), works in preventing the risk of HIV.

Active, not recruiting
Pre-Exposure Prophylaxis of HIV Infection
Drug: PTM F/TDF
Drug: Placebo SC LEN

Trial sponsors

Kaiser Permanente logo
Vertex Pharmaceuticals logo
Gilead Sciences logo
Concert Pharmaceuticals logo
AbbVie logo
AstraZeneca logo
Bristol-Myers Squibb (BMS) logo
Jazz Pharmaceuticals logo
Loxo Oncology logo
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems